NK cell therapy, explained

Your own natural-killer cells, expanded and returned — a licensed disease treatment, not a wellness product. What it is, who it is for, and what it cannot do.

What an NK cell is

Natural killer cells are a class of white blood cell in the innate immune system. Unlike T cells, which must first learn to recognise a specific target, NK cells patrol the body and destroy cells that have lost the normal “self” markers on their surface — a signature shared by many virus-infected cells and by tumour cells trying to evade detection. They are, in the immunologist’s phrase, the first responders. Their number and their activity decline with age, after chemotherapy or radiation, and in the months after major surgery, which is precisely when the body would most like to have them.

Autologous NK therapy is the attempt to restore that surveillance directly. A sample of your blood is drawn, the NK fraction is separated and expanded in a licensed GMP cleanroom over roughly two weeks — typically to many times its starting number — released only after passing viability, identity, sterility and endotoxin panels, and then reinfused. Autologous means the cells are your own: there is no donor, no matching, and no rejection question. How cell products are released, and what the zone requires →

What it is licensed for here

This is the part that matters most, and the part most often blurred elsewhere. At Boao Lecheng, autologous NK therapy is delivered by the zone’s tertiary hospitals as a disease-treatment program under the pilot zone’s clinical-stage licensing. The licensed indications, as filed by the treating hospital, are:

What is not on that list: longevity, rejuvenation, “immune optimisation” for the healthy, or any general wellness use. Mainland regulation now confines cell therapy to disease indications, and the zone’s hospitals hold their licences on that basis. If a clinic anywhere offers you NK cells to feel younger, that is a different — and, on the mainland, unlicensed — proposition. The retreat’s wellness side is built on the six-axis system, not on cells.

How a course runs

A full course therefore spans about five weeks. Guests handle this in one of three ways: an extended island stay that covers the whole course, the first infusion during the retreat with returns for the second and third, or — for those living in East Asia — three short visits. Hainan’s 30-day visa-free entry covers the first two comfortably; the treating hospital can support a stay extension on medical grounds where the course requires it.

Who is declined

The treating hospital’s panel applies the licensed inclusion criteria before anything else is discussed, and some guests are declined. The filed criteria are: age eighteen or over; an ECOG performance status of 0 to 2 (broadly, able to care for oneself and up and about for at least half of waking hours); a Child-Pugh score of 7 or below where liver function is relevant; an expected prognosis of at least three months; and negative screening for hepatitis B, hepatitis C, HIV and syphilis. Active uncontrolled infection, certain autoimmune conditions and some concurrent treatments are also exclusions, decided case by case.

What it cannot do

NK cell therapy does not replace surgery, chemotherapy, radiation or targeted drugs, and it is not offered as an alternative to any of them. It is an adjunct: an attempt to lower the odds of recurrence, or rebuild immune function, alongside the plan your oncologist has already set. It is clinical-stage medicine — lawful inside the zone precisely because outcomes are still being gathered — and every course is reported into China’s national real-world data program as a condition of the licence. No hospital in the zone may promise an outcome, and nor will we.

It is also not a one-time fix. NK cells are short-lived in circulation; the rationale for scheduled infusions, and for the follow-up measurements, is that the effect has to be maintained and checked, not assumed.

Why the zone, for this

Three things are true only here on the mainland. The therapy is licensed, delivered in tertiary hospitals rather than clinics, across five approval batches of cell and gene technologies. The cells are manufactured on-site, in the hospitals’ own GMP facilities, so there is no cold-chain transfer between manufacturer and bedside. And outcome reporting is mandatory: the zone reports into a national real-world data program, which is the closest thing to a clinical trial framework a patient can enter outside of one. Why Boao Lecheng →

If you have had a solid tumour resected in the past two years, or are finishing checkpoint-inhibitor therapy, and your oncologist is open to an adjunct, write to us with the outline of your history. A care manager will tell you honestly, within one working day, whether the panel is likely to consider you — before you plan a trip around it.